Journal of Clinical Endocrinology & Metabolism, Vol 78, 818-823, Copyright © 1994 by Endocrine Society

ARTICLES

Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women

C Marcocci, F Golia, G Bruno-Bossio, E Vignali and A Pinchera
Istituto di Endocrinologia, Universita di Pisa, Italy.

We measured total body and regional (lumbar spine, femoral neck, Ward's triangle, and trochanter) bone mineral density (BMD) in 47 premenopausal women chronically treated with suppressive doses of levothyroxine (L-T4). Treatment was administered to 7 patients with nontoxic goiter or, after thyroidectomy, to 38 patients with differentiated thyroid cancer and 2 with nontoxic goiter. Patients were followed at our institution and treated with the minimal amount of L-T4 necessary to suppress TSH. At the time of evaluation, free T3 was normal in all cases, whereas free T4 was increased in 17 (36.2%). The mean daily dose of L-T4 was 154.3 +/- 5 micrograms, and the mean duration of treatment was 10.1 yr. We found no significant difference between patients and age- and weight-matched controls in BMD at any site of measurement. BMD was not correlated with duration of therapy, cumulative or mean daily dose of L-T4, serum levels of free T4, free T3, and osteocalcin. There was no difference between patients and controls in serum total calcium, intact PTH, osteocalcin, or carboxy- terminal cross-linked telopeptide of type I collagen or in the concentrations of two markers of thyroid hormone action (sex hormone- binding globulin and amino-terminal propeptide of type III procollagen). Our data suggest that L-T4 suppressive therapy, if carefully carried out and monitored, using the smallest dose necessary to suppress TSH secretion has no significant effect on bone metabolism or bone mass.

This article has been cited by other articles:

				B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]

				B. Lentle and D. Worsley Osteoporosis Redux J. Nucl. Med., December 1, 2006; 47(12): 1945 - 1959. [Full Text] [PDF]

				J L Reverter, S Holgado, N Alonso, I Salinas, M L Granada, and A Sanmarti Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma Endocr. Relat. Cancer, December 1, 2005; 12(4): 973 - 981. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]

				C. Marcocci, L. Bartalena, M. L. Tanda, L. Manetti, E. Dell'Unto, R. Rocchi, G. Barbesino, B. Mazzi, M. P. Bartolomei, P. Lepri, et al. Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves' Ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3562 - 3567. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				R. C. Pereira, V. Jorgetti, and E. Canalis Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E496 - E504. [Abstract] [Full Text] [PDF]

				S. L. Greenspan and F. S. Greenspan The Effect of Thyroid Hormone on Skeletal Integrity Ann Intern Med, May 4, 1999; 130(9): 750 - 758. [Abstract] [Full Text] [PDF]

				A. Siddiqi, J. P. Monson, D. F. Wood, G. M. Besser, and J. M. Burrin Serum Cytokines in Thyrotoxicosis J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 435 - 439. [Abstract] [Full Text]

				H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330. [Abstract] [Full Text]

				R. A. Nordyke, T. S. Reppun, L. D. Madanay, J. C. Woods, A. P. Goldstein, and L. A. Miyamoto Alternative Sequences of Thyrotropin and Free Thyroxine Assays for Routine Thyroid Function Testing: Quality and Cost Arch Intern Med, February 9, 1998; 158(3): 266 - 272. [Abstract] [Full Text] [PDF]

				M. J. Schlumberger Papillary and Follicular Thyroid Carcinoma N. Engl. J. Med., January 29, 1998; 338(5): 297 - 306. [Full Text] [PDF]

				S. K. G. Grebe, R. R. Cooke, H. C. Ford, J. N. Fagerstrom, D. P. Cordwell, N. A. Lever, G. L. Purdie, and C. M. Feek Treatment of Hypothyroidism with Once Weekly Thyroxine J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 870 - 875. [Abstract] [Full Text] [PDF]

				J. M. LANE, E. H. RILEY, and P. Z. WIRGANOWICZ Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis: Diagnosis and Treatment*{{dagger}} J. Bone Joint Surg. Am., April 1, 1996; 78(4): 618 - 32. [Full Text]